Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | GAPDH | P04406 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL12352425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL1821276 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL13362239 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL24538665 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2228590 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23804425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL406207 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23420216 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2403819 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL19107495 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488598-B2 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY ENTERPRISE AND COMMERCIALIZATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7037718-B2 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION | 2005-09-29 | — | — | US | disclosed |
| EP-0543913-B1 | OLIGO(ALPHA-ARABINOFURANOSYL NUCLEOTIDES) AND ALPHA-ARABINOFURANOSYL PRECURSORS THEREOF | EPOCH PHARMACEUTICALS INC (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0543913-A4 | OLIGO(ALPHA-ARABINOFURANOSYL NUCLEOTIDES) AND ALPHA-ARABINOFURANOSYL PRECURSORS THEREOF | MICROPROBE CORP (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0672193-A1 | OLIGONUCLEOTIDES HAVING A CONSERVED G 4? CORE SEQUENCE | ISIS PHARMACEUTICALS, INC. (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994008053-A1 | OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE | ISIS PHARMACEUTICALS, INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| EP-0543913-A1 | OLIGO(ALPHA-ARABINOFURANOSYL NUCLEOTIDES) AND ALPHA-ARABINOFURANOSYL PRECURSORS THEREOF | EPOCH PHARMACEUTICALS, INC. (US) | 1993-06-02 | — | — | EP | disclosed |
| US-5177196-A | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof | MICROPROBE CORPORATION (US) | 1993-01-05 | — | — | US | disclosed |
| WO-1992003577-A1 | OLIGO(ALPHA-ARABINOFURANOSYL NUCLEOTIDES) AND ALPHA-ARABINOFURANOSYL PRECURSORS THEREOF | MICROPROBE CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
| EP-0097376-A1 | Nucleoside 5'-alkyl- or alkenylphosphate | Yamasa Shoyu Kabushiki Kaisha (JP) | 1984-01-04 | — | — | EP | disclosed |
| EP-0042596-A1 | Novel adenine nucleoside derivatives, their preparation and pharmaceutical compositions containing them | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | PNP, UPP1, TYMP | ADORA3 974/4885ADORA2A 475/4885ADORA2B 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.